Foghorn Therapeutics (FHTX) announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. Gallagher serves as the President, Head of Research and Development at Syndax Pharmaceuticals. Duty, most recently, served as a Senior Managing Director at Guggenheim Securities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics: Buy Rating Backed by Innovative Oncology Approaches and Promising Clinical Developments
- Foghorn Therapeutics announces new preclinical data at AACR
- Foghorn Therapeutics Presents Preclinical Data at AACR 2025
- Foghorn Therapeutics initiated with an Outperform at Citizens JMP
- Promising Advancements and Strategic Collaborations Position Foghorn Therapeutics as a Strong Buy